Ondine Biomedical targets US regulatory milestone after £10m raise and positive Phase 3 results

Podcast: Proactive - Interviews for investors · Proactive

Opublikowano: 2026-10-21

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) President and Chief Technology Officer Nicolas Loebel spoke with Proactive's Stephen Gunnion about the company’s £10 million fundraising, positive top-line Phase 3 results and plans to bring its nasal photodisinfection technology to the US market. Loebel discussed the timing of the raise, completed at 10p per share, following the LANTERN Phase 3 trial involving 5,188 patients across 18 hospitals in the US and Canada. “Our top line results have just come through. They're very good,” he says. The company is now completing detailed analysis of the clinical data ahead of its next regulatory steps. Ondine is targeting a pre-N...